Durect Corp (NAS:DRRX)
$ 1.06 -0.07 (-6.19%) Market Cap: 32.90 Mil Enterprise Value: 23.96 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 52/100

DURECT Corporation Key Opinion Leader Call on Psoriasis Transcript

Mar 29, 2019 / 03:00PM GMT
Release Date Price: $6.26 (-3.69%)
Operator

Good day, and welcome to the Key Opinion Leader Call on Psoriasis hosted by DURECT Corporation. (Operator Instructions) At this time, I would like turn the conference over to Mr. Mike Arenberg, Chief Financial Officer of DURECT Corporation. Please go ahead.

Michael H. Arenberg
DURECT Corporation - CFO

Welcome to our Key Opinion Leader Call on Psoriasis. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. This call will begin with a presentation by Dr. Howard Maibach on psoriasis, including an overview of the disease, current treatment options and the treatment landscape for psoriasis. This will be followed by a presentation by Jim Brown, DURECT's President and CEO, on our Phase IIa study on psoriasis with DUR-928, followed by a Q&A session.

Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's business and DUR-928. These forward-looking statements involve risks and uncertainties that can cause actual results to differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot